MedTrace Logo

To Evaluate the Response to Glucagon During Hypoglycemia

NCT00817271 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2009-05-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the response to Glucagon versus the spontaneous hormonal response to low blood sugar levels in T2DM Patients treated with AZD1656 and Metformin

Conditions

Interventions

DRUG

AZD1656

Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose

DRUG

Glucagon

1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD, PhD, Prof. · AstraZeneca R&D Mölndal

  • Marcus Hompesch, MD · Profil Institut for Clinical Research Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00817271 on ClinicalTrials.gov